Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma

AbstractBackgroundPD-1/PD-L1 inhibitors is the important drugs of immunotherapy for malignant tumors. PD-L1 expression is an important biomarker of selecting patients for ICIs therapy. However, the correlation of PD-L1 expression with clinicopathologic features in lung adenocarcinoma remains controversial.MethodsPD-L1 expression was tested using clone SP263 by immunohistochemistry (IHC) on Ventana automated Benchmark in tissue micro-arrays (TMA) in lung adenocarcinoma. The association of PD-L1 expression with clinicopathologic characteristics, including gender, age, histological subtype, smoking history, stage, and genotype were analyzed.Results404 patients were available for analyzing. The incidence of PD-L1 expression was 22.5% (using a cutoff of ≥ 25%). Statistical analysis showed PD-L1 expression was associated with advanced stage, lymph node (LN) metastasis, solid predominant subtype and wild-type epidermal growth factor receptor (EGFR) gene. In subgroup analysis, PD-L1 expression in patients with EGFR exon 19 deletions was higher tha n that of with EGFR L858R mutation at exon 21 (21.6% vs. 10.2%,P = 0.046). In multivariate analysis for overall survival (OS) by Cox hazard proportion model, patients with EGFR gene mutations (HR 1.635, 95% CI 1.310–2.040,P 
Source: Interdisciplinary Sciences, Computational Life Sciences - Category: Bioinformatics Source Type: research

Related Links:

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection. Immunotherapies for the trea...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Karamouzis Immune checkpoint inhibitors have revolutionized cancer treatment in the last decade. Despite the progress in immunotherapy, most pancreatic cancer patients still do not derive benefit when receiving immune-based therapies. Recently, resistance mechanisms to immune therapies have been mainly focused on tumor microenvironment properties. Pancreatic cancer is considered one of the most lethal and difficult to treat tumors due to its highly immunosuppressive and desmoplastic microenvironment. Low molecular weight heparins (LMWHs) have been used for the treatment and prevention of thromboembolic disease in the...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionThis proof-of-concept study suggests that a combination of PD-L1 expression, TML, CD8+ T cell infiltration and HLA class-I functions as a better predictive biomarker for response to anti-PD-1 immunotherapy. Consequently, refinement of this set of biomarkers and validation in a larger set of patients is warranted.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
CONCLUSION: This study is planned to include 32 patients to evaluate the pCR-R with the combination of nivolumab and ipilimumab in neoadjuvant setting for MSI/dMMR localized GOA. The MSI/MMR status should be systematically assessed on diagnostic biopsies of all GOA. If it meets its primary endpoint, the GERCOR NEONIPIGA study might mark a turning point in the management of localized MSI/dMMR GOA patients. PMID: 32057467 [PubMed - as supplied by publisher]
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
AbstractCancer is one of the main causes of mortality worldwide and a major public health concern. Among various strategies, therapeutic vaccines have been developed to stimulate anti-tumoral immune responses. However, in spite of extensive studies, this approach suffers from a lack of efficacy. Recently, we designed the MAG-Tn3 vaccine, aiming to induce antibody responses against Tn, a tumor-associated carbohydrate antigen. The Tn antigen is of interest because it is expressed by several adenocarcinomas, but not normal cells. The fully synthetic glycopeptide vaccine MAG-Tn3 is composed of four arms built on three adjacent...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Tumour cells interfere with normal immune functions by affecting the expression of some immune-related genes, which play roles in the prognosis of cancer patients. In recent years, immunotherapy for tumours ha...
Source: Journal of Translational Medicine - Category: Research Authors: Tags: Research Source Type: research
AbstractProstate cancer is a candidate for immunotherapy because cancer cells express tissue-specific proteins that can be therapeutic targets. However, immune checkpoint inhibitors and active immunization have performed poorly in clinical trials. We developed a novel virus-like particle (VLP) vaccine composed of bovine papillomavirus L1 protein engineered to display surface docking sites. We decorated VLPs with peptides encoding T cell epitopes from two prostate cancer-associated tumor antigens, prostate stem cell antigen (PSCA), and prostatic acid phosphatase (PAP-1 and PAP-2), and a neo-antigen, stimulator of prostatic ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Contributors : Marcus Ruscetti ; John Morris IV ; Riccardo Mezzadra ; James Russell ; Josef Leibold ; Paul B Romesser ; Janelle Simon ; Amanda Kulick ; Yu-jui Ho ; Myles Fennell ; Jinyang Li ; Robert J Norgard ; John E Wilkinson ; Direna Alonso-Curbelo ; Ramya Sridharan ; Daniel A Heller ; Elisa de Stanchina ; Ben Z Stanger ; Charles J Sherr ; Scott LoweSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusKRAS mutant pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic response that promotes hypovascularity, immunosuppression, and resistance to chemo- and immunotherap...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
This article discusses the molecular characteristics of the main lung cancer subtypes and discusses the current guidelines and novel targeted therapies, including checkpoint immunotherapy. PMID: 32005431 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Surg Pathol Clin Source Type: research
Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), p...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Bioinformatics | Cancer & Oncology | Genetics | Immunotherapy | Smokers | Statistics